Apogee Change In Cash from 2010 to 2026

APGE Stock   69.64  1.86  2.74%   
Apogee Therapeutics' Change In Cash is decreasing over the years with slightly volatile fluctuation. Overall, Change In Cash is expected to go to about 37.9 M this year. During the period from 2010 to 2026 Apogee Therapeutics Change In Cash annual values regression line had coefficient of variation of  52.52 and r-squared of  0.49. View All Fundamentals
 
Change In Cash  
First Reported
2010-12-31
Previous Quarter
21.1 M
Current Value
37.9 M
Quarterly Volatility
62.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Apogee Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apogee Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 42 M, Interest Income of 42 M or Depreciation And Amortization of 161.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.42. Apogee financial statements analysis is a perfect complement when working with Apogee Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Apogee Stock
Check out the analysis of Apogee Therapeutics Correlation against competitors.
Analyzing Apogee Therapeutics's Change In Cash over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Change In Cash has evolved provides context for assessing Apogee Therapeutics's current valuation and future prospects.

Latest Apogee Therapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Apogee Therapeutics Common over the last few years. It is Apogee Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apogee Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Slightly volatile
   Change In Cash   
       Timeline  

Apogee Change In Cash Regression Statistics

Arithmetic Mean119,045,735
Coefficient Of Variation52.52
Mean Deviation50,232,405
Median151,890,000
Standard Deviation62,517,874
Sample Variance3908.5T
Range185.2M
R-Value(0.70)
Mean Square Error2140.2T
R-Squared0.49
Significance0
Slope(8,636,548)
Total Sum of Squares62535.8T

Apogee Change In Cash History

202637.9 M
202521.1 M
202423.5 M
2023-33.3 M

About Apogee Therapeutics Financial Statements

Apogee Therapeutics stakeholders use historical fundamental indicators, such as Apogee Therapeutics' Change In Cash, to determine how well the company is positioned to perform in the future. Although Apogee Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Apogee Therapeutics' assets and liabilities are reflected in the revenues and expenses on Apogee Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Apogee Therapeutics Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Cash21.1 M37.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Apogee Therapeutics is a strong investment it is important to analyze Apogee Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics' future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:
Check out the analysis of Apogee Therapeutics Correlation against competitors.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Biotechnology sector continue expanding? Could Apogee diversify its offerings? Factors like these will boost the valuation of Apogee Therapeutics. If investors know Apogee will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apogee Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.38)
Return On Assets
(0.25)
Return On Equity
(0.38)
Investors evaluate Apogee Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Apogee Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Apogee Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Apogee Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apogee Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Apogee Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.